IBB — iShares Biotechnology ETF
Healthcare Ranked #107 of 458 tracked ETFs · Issued by iShares
IBB Price Performance — Growth of $10,000
Value of a $10,000 investment in IBB over time, compared with SPY. Both lines are rebased to $10,000 on the first shared date. Based on total returns — prices are adjusted for dividends and splits, so this assumes distributions were reinvested. Hover or tap the chart for exact values.
IBB Drawdown
The "underwater" chart: IBB's decline from its highest prior value at each point in time. It shows how deep past losses ran and how long the fund took to recover to break-even.
What If You'd Invested in IBB?
See what a lump sum in IBB would have grown to, with the option to add a regular monthly contribution on top. Figures use total returns — dividends are assumed reinvested.
Past performance doesn't predict future results. Assumes contributions on the first trading day of each month, no trading costs or taxes, and reinvested distributions. History is limited to the range published in the site's daily return data.
Overview
The iShares Biotechnology ETF (IBB) operates within the Healthcare category, which currently contains 11 funds tracked by ETFValuer. Issued by iShares, this fund has accumulated assets under management of $9.09 billion and trades at a price of $190.52. It holds an overall rank of #107 out of 458 tracked ETFs across all categories and has received an ETFValuer grade of B with a score of 70.0 out of 100. The fund charges an expense ratio of 0.44% and offers a dividend yield of 0.19%. The substantial asset size and specific price point suggest a level of investor adoption consistent with a major thematic exposure within the healthcare sector. These metrics collectively define the fund's structural profile and cost efficiency relative to its peers.
Over the last day, the fund posted a return of +1.16%, followed by a weekly gain of +0.64% and a monthly increase of +1.69%. The three-month performance accelerated significantly to +12.74%, while the six-month return stood at +8.44%. Year-to-date gains reached +12.83%, and the one-year return surged to +40.96%. This upward trajectory continued into the three-year period, which recorded a total return of +50.85%. The data indicates a pattern where recent short-term gains align with strong longer-term momentum, particularly evident in the one-year and three-year horizons.
The fund carries a Moderate volatility label and a beta of 0.69, suggesting price movements that are generally less sensitive to broad market fluctuations. A Sharpe ratio of 1.77 indicates that the returns generated have been efficient relative to the risk taken during the measurement period. However, the maximum drawdown of -24.85% highlights the potential for significant temporary declines in value during adverse market conditions. This combination of a low beta and high Sharpe ratio implies that while the fund may experience periods of sharp decline, it has historically provided substantial compensation for that risk. Investors should note that the moderate volatility classification aligns with the observed drawdown magnitude and the fund's beta profile.
AI-generated summary based on the data on this page.
IBB Top Holdings
| # | Holding | % of Net Assets | Value |
|---|---|---|---|
| 1 | BlackRock Funds III | 13.18% | $783M |
| 2 | Vertex Pharmaceuticals, Inc. | 7.66% | $455M |
| 3 | Gilead Sciences, Inc. | 7.52% | $447M |
| 4 | Amgen, Inc. | 7.50% | $446M |
| 5 | Regeneron Pharmaceuticals, Inc. | 5.70% | $339M |
| 6 | Alnylam Pharmaceuticals, Inc. | 5.68% | $337M |
| 7 | IQVIA Holdings, Inc. | 3.18% | $189M |
| 8 | Argenx SE | 3.15% | $187M |
| 9 | Insmed, Inc. | 2.95% | $176M |
| 10 | Mettler-Toledo International, Inc. | 2.49% | $148M |
Holdings as of 2025-09-30 per the fund's most recent SEC N-PORT-P filing. Top 10 holdings make up 59.0% of net assets — a rough gauge of concentration risk (the higher this figure, the more the fund's return depends on a handful of names). To see how IBB's holdings overlap with other ETFs you own or are considering, check the Stock Overlap tool.
Which Funds Overlap With IBB
Holding two funds that own the same companies adds cost and complexity without adding much diversification. These tracked ETFs share the most names with IBB's top 10 — IWP overlaps most, holding 2 of the same companies as IBB's top 10 (18.9% of IBB's assets).
| ETF | Name | Shared Companies | IBB Weight | Examples |
|---|---|---|---|---|
| IWP | iShares Russell Mid-Cap Growth ETF | 2 | 18.9% | BlackRock Funds III, Alnylam Pharmaceuticals, Inc. |
| VHT | Vanguard Health Care Index Fund ETF Shares | 2 | 15.0% | Amgen, Inc., Gilead Sciences, Inc. |
| XLV | State Street Health Care Select Sector SPDR ETF | 2 | 15.0% | Amgen, Inc., Gilead Sciences, Inc. |
| FHLC | Fidelity MSCI Health Care Index ETF | 2 | 15.0% | Amgen, Inc., Gilead Sciences, Inc. |
| IYH | iShares U.S. Healthcare ETF | 2 | 15.0% | Amgen, Inc., Gilead Sciences, Inc. |
Compares the top 10 reported holdings of each fund, so it's a floor on true overlap — two S&P 500 trackers overlap ~100% even when only 10 names are listed. Use the Stock Overlap tool to search by individual company.
Market Backdrop
10-Year Treasury Yield: 4.65% (as of 2026-07-27) — The yield on 10-year US Treasury bonds — the standard "risk-free rate" benchmark used to contextualize this fund’s Sharpe ratio and returns.
CBOE Volatility Index (VIX): 18.67 (as of 2026-07-27) — A real-time gauge of expected S&P 500 volatility over the next 30 days — useful context for this fund’s own volatility label.
Federal Funds Rate: 3.63% (as of 2026-06-01) — The Federal Reserve’s target policy rate, which anchors short-term borrowing costs across the economy.
What IBB's Fees Cost You
IBB charges an expense ratio of 0.44% a year, deducted automatically from the fund's value. Small percentages compound into real money — adjust the figures below to see the impact on your own numbers.
Assumes a constant gross return and no additional contributions — a simplification, but it isolates exactly what the expense ratio costs. Try the full fee calculator to model contributions and compare any two funds.
IBB Dividend Income Estimator
IBB currently yields 0.19%. Enter an amount to see the income that implies, or set a monthly income target to see the investment it would take.
Based on the fund's current trailing yield, which varies with price and distributions — treat it as an estimate, not a guarantee. Yields are not adjusted for tax.
IBB Liquidity, Domicile & Tax Treatment
Liquidity: Quoted bid/ask spread is 5.68% and average daily volume is 1.5M/day. Tighter spreads and higher volume mean lower round-trip trading costs; this is a live-market snapshot and can widen during volatile sessions. AUM of $9.09B provides ample scale, supporting tight spreads and issuer commitment to keep the fund open.
Domicile & tax treatment: IBB is a US-domiciled, SEC-registered ('40 Act) exchange-traded fund. Dividends and capital gains distributions are reported to US investors on Form 1099-DIV, and the fund is not subject to the PFIC reporting or UCITS-specific rules that apply to Irish- or Luxembourg-domiciled funds. Non-US investors should note that US-domiciled ETFs are generally subject to 30% US withholding tax on dividends (unless reduced by treaty) and to US estate tax exposure on the position — Irish-domiciled UCITS ETFs tracking the same index often avoid both, which is why non-US residents frequently prefer the UCITS equivalent where one exists. This is general information, not tax advice — consult a tax professional for your situation.
IBB Performance History
| Period | Return |
|---|---|
| 1-Day | +1.16% |
| 1-Week | +0.64% |
| 1-Month | +1.69% |
| 3-Month | +12.74% |
| 6-Month | +8.44% |
| YTD | +12.83% |
| 1-Year | +40.96% |
| 3-Year | +50.85% |
How IBB Compares to Other Healthcare ETFs
| Rank | Grade | Ticker | Name | 1-Year | Exp. Ratio | AUM |
|---|---|---|---|---|---|---|
| #50 | B |
VHT | Vanguard Health Care Index Fund ETF Shares | +26.69% | 0.09% | $20.4B |
| #58 | B |
XLV | State Street Health Care Select Sector SPDR ETF | +24.69% | 0.08% | $40.6B |
| #60 | B |
XBI | State Street SPDR S&P Biotech ETF | +71.74% | 0.35% | $10.7B |
| #86 | B |
FHLC | Fidelity MSCI Health Care Index ETF | +26.80% | 0.084% | $3.22B |
| #107 | B |
IBB | iShares Biotechnology ETF | +40.96% | 0.44% | $9.09B |
| #112 | B |
XPH | State Street SPDR S&P Pharmaceuticals ETF | +60.44% | 0.35% | $428M |
| #146 | B |
PPH | VanEck Pharmaceutical ETF | +29.37% | 0.36% | $879M |
| #167 | B |
IYH | iShares U.S. Healthcare ETF | +24.12% | 0.38% | $3.16B |
| #232 | C |
IHF | iShares U.S. Healthcare Providers ETF | +37.30% | 0.38% | $1.18B |
| #383 | D |
ARKG | ARK Genomic Revolution ETF | +45.46% | 0.75% | $1.73B |
| #443 | F |
IHI | iShares U.S. Medical Devices ETF | -13.86% | 0.38% | $3.02B |